The Impact on Health Outcomes and Healthcare Utilisation of Switching to Generic Medicines Consequent to Reference Pricing: The Case of Lamotrigine in New Zealand

RT @PeterByardDavis: Contrary to tenor of RNZ story on PHARMAC and epilepsy drug, switching ongoing since mid-2000s. Our study https://t.co…

Contrary to tenor of RNZ story on PHARMAC and epilepsy drug, switching ongoing since mid-2000s. Our study https://t.co/I71JemH3HA suggests no evidence of adverse outcomes. ://www.rnz.co.nz/news/in-depth/399908/seizures-driving-stand-downs-as-pharmac-pulls-

@radionz @GuyonEspiner In our PhD study of switches for this drug, there were no obvious differences in outcomes using available data. https://t.co/I71JemH3HA. Obviously there will be some individuals who find difficulties, but as far as we could tell, ove

#HealthEconJA The Impact on Health Outcomes and Healthcare Utilisation of Switching to Generic Medicines Consequ... http://t.co/tpkTumDfy7

#HealthEconJA The Impact on Health Outcomes and Healthcare Utilisation of Switching to Generic Medicines Consequ... http://t.co/tpkTumDfy7